Lingvay, Ildiko

12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2025

American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Callaghan, B. C., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care

Diabetic Foot Ulcer Assessment and ManagementDiabetes Management and Research

Cited by 176

14. Children and Adolescents: Standards of Care in Diabetes—2025

American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care

Diabetes Management and ResearchDiabetes Management and Education

Cited by 173

13. Older Adults: Standards of Care in Diabetes—2024

American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 161

Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

Leiter, L. A., Bain, S. C., Hramiak, I., Jódar, E., Madsbad, S., Gondolf, T., Hansen, T., Holst, I., & Lingvay, I. (2019) · Cardiovascular Diabetology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 159

Introduction and Methodology: Standards of Care in Diabetes—2025

American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Callaghan, B. C., et al. (2025) · Diabetes Care

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 155

Association of Statin Therapy Initiation With Diabetes Progression: A Retrospective Matched-Cohort Study

Mansi, I. A., Chansard, M., Lingvay, I., Zhang, S., Halm, E. A., & Alvarez, C. A. (2021) · JAMA Internal Medicine

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 144

Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

Davies, M. J., Bajaj, H. S., Broholm, C., Eliasen, A., Garvey, W. T., le Roux, C. W., Lingvay, I., Lyndgaard, C. B., Rosenstock, J., & Pedersen, S. D. (2025) · New England Journal of Medicine

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 143

Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial

Deanfield, J., Lincoff, A. M., Kahn, S. E., Emerson, S. S., Lingvay, I., Scirica, B. M., Plutzky, J., Kushner, R. F., Colhoun, H. M., Hovingh, G. K., et al. (2025) · The Lancet

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 143

Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity

Wharton, S., Lingvay, I., Bogdanski, P., Duque do Vale, R., Jacob, S., Karlsson, T., Shaji, C., Rubino, D., & Garvey, W. T. (2025) · New England Journal of Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 142

Once-Weekly Semaglutide 7·2 Mg in Adults with Obesity (STEP UP): A Randomised, Controlled, Phase 3b Trial

Wharton, S., Freitas, P., Hjelmesæth, J., Kabisch, M., Kandler, K., Lingvay, I., Quiroga, M., Rosenstock, J., & Garvey, W. T. (2025) · The Lancet Diabetes & Endocrinology

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 119

Rapid improvement in diabetes after gastric bypass surgery

Lingvay, I., Guth, E., Islam, A., & Livingston, E. (2013) · Diabetes Care

Bariatric Surgery and OutcomesMinimally Invasive Surgical Techniques

Cited by 116

Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics

Lingvay, I., Brown‐Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt‐Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · Obesity

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 113

Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program

Perreault, L., Davies, M., Frias, J. P., Laursen, P. N., Lingvay, I., Machineni, S., Varbo, A., Wilding, J. P. H., Wallenstein, S. O. R., & le Roux, C. W. (2022) · Diabetes Care

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 87

Effectiveness of semaglutide versus liraglutide for treating post‐metabolic and bariatric surgery weight recurrence

Murvelashvili, N., Xie, L., Schellinger, J. N., Mathew, M. S., Marroquin, E. M., Lingvay, I., Messiah, S. E., & Almandoz, J. P. (2023) · Obesity

Bariatric Surgery and OutcomesPharmacology and Obesity Treatment

Cited by 86

A 26-week randomized controlled trial of semaglutide once daily versus liraglutide and placebo in patients with type 2 diabetes suboptimally controlled on diet and exercise with or without metformin.

Lingvay, I., Desouza, C. V., Lalic, K. S., Rose, L., Hansen, T., Zacho, J., & Pieber, T. R. (2018) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 81

Use of Lipid-, Blood Pressure–, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

Nelson, A. J., O’Brien, E. C., Kaltenbach, L. A., Green, J. B., Lopes, R. D., Morse, C. G., Al-Khalidi, H. R., Aroda, V. R., Cavender, M. A., Gaynor, T., et al. (2022) · JAMA Network Open

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 78

Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance

Almandoz, J. P., Lingvay, I., Morales, J., & Campos, C. (2020) · Clinical Diabetes

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 74

Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events

Lingvay, I., Hansen, T., Macura, S., Marre, M., Nauck, M. A., de la Rosa, R., Woo, V., Yildirim, E., & Wilding, J. (2020) · BMJ Open Diabetes Research & Care

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 71

Pharmacotherapies for post-bariatric weight regain: real-world comparative outcomes

Gazda, C. L., Clark, J. D., Lingvay, I., & Almandoz, J. P. (2021) · Obesity

Bariatric Surgery and OutcomesPharmacology and Obesity Treatment

Cited by 56

Effect of medication adherence on clinical outcomes in type 2 diabetes: analysis of the SIMPLE study

Patel, S., Abreu, M., Tumyan, A., Adams-Huet, B., Li, X., & Lingvay, I. (2019) · BMJ Open Diabetes Research & Care

Medication Adherence and ComplianceDiabetes Treatment and Management

Cited by 56

Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program.

Lingvay, I., Mosenzon, O., Brown, K., Cui, X., O’Neill, C., Fernández Landó, L., & Patel, H. (2023) · Cardiovascular Diabetology

Diabetes Treatment and ManagementBlood Pressure and Hypertension Studies

Cited by 55

Effect of pioglitazone on plasma ceramides in adults with metabolic syndrome

Warshauer, J. T., Lopez, X., Gordillo, R., Hicks, J., Holland, W. L., Anuwe, E., Blankfard, M. B., Scherer, P. E., & Lingvay, I. (2015) · Diabetes/Metabolism Research and Reviews

Sphingolipid Metabolism and SignalingAdipokines, Inflammation, and Metabolic Diseases

Cited by 51

The Effect of Semaglutide on Mortality and COVID-19–Related Deaths

Scirica, B. M., Lincoff, A. M., Lingvay, I., Bogdanski, P., Buscemi, S., Colhoun, H., Craciun, A.-E., Ezhov, M., Hardt-Lindberg, S., Kleist Jeppesen, O., et al. (2024) · Journal of the American College of Cardiology

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 51

Erratum. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024. Diabetes Care 2024;47(Suppl. 1):S158–S178

American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 45